...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pathology International >Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.
【24h】

Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.

机译：通过p53和血红蛋白F的免疫染色以及核型分析来表征骨髓增生异常综合症和再生障碍性贫血：难治性贫血和再生障碍性贫血之间的鉴别诊断。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

P53 mutation has been reported in various solid tumors, acute leukemia and myelodysplastic syndrome (MDS), but the diagnostic significance of p53 in MDS remains to be determined. The purpose of the present paper was to examine p53 mutation and immunostaining of the same patients, because there have been few reports of simultaneous analysis of these markers. Seven p53 mutations were observed among 37 MDS and 11 cases of overt leukemia transformed from MDS (MDS-OL). Mutated p53 mainly observed in high-risk MDS had more intense p53 staining than in MDS with wild-type p53 overexpression. Aplastic anemia (AA) produced no p53 staining. The percentage of p53 staining in MDS (71%) was higher than that of mutated p53 (11%) but did not reach 100% of MDS cases studied, therefore the authors attempted to differentiate MDS, especially refractory anemia (RA) and AA, using a combination of p53 immunostaining, hemoglobin F (HbF) immunostaining and chromosome abnormality, because HbF of erythroblasts was reportedly observed in MDS RA but not in AA. Most MDS/MDS-OL (47/48) had at least one positive marker. Among 11 AA cases, only two were positive for HbF. The present results suggest that the combination of these three markers is useful to discriminate MDS from AA.
机译：在各种实体瘤，急性白血病和骨髓增生异常综合症（MDS）中已报道P53突变，但p53在MDS中的诊断意义尚待确定。本文的目的是检查同一患者的p53突变和免疫染色，因为很少有同时分析这些标志物的报道。在37个MDS和11例由MDS（MDS-OL）转化的明显白血病中观察到7个p53突变。主要在高危MDS中观察到的突变p53具有比野生型p53过表达的MDS更强烈的p53染色。再生障碍性贫血（AA）未产生p53染色。 MDS中p53染色的百分比（71％）高于突变的p53（11％），但未达到所研究MDS病例的100％，因此，作者试图区分MDS，特别是难治性贫血（RA）和AA，结合使用p53免疫染色，血红蛋白F（HbF）免疫染色和染色体异常，因为据报道在MDS RA中观察到成红细胞的HbF，而在AA中未观察到。大多数MDS / MDS-OL（47/48）具有至少一种阳性标记。在11例AA病例中，只有2例HbF阳性。目前的结果表明，这三种标记物的组合可用于区分MDS和AA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号